Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
89.00 50.77 138.79 205.56 168.10 113.18 48.21 267.52 0.00 188.34
Piotroski F-Score
3 5 5 5 6 5 4 4 4 6
P/S ratio
10.00 10.03 11.90 16.55 27.50 21.73 11.21 15.80 12.69 12.48
Altman Z-Score
6.10 6.02 9.27 8.68 16.90 15.29 10.18 7.83 6.42 7.49
P/FCF ratio
322.68 118.11 115.48 101.49 277.58 305.20 107.29 133.33 83.67 215.98
Altman Z″-Score (non-manufacturers)
4.87 6.00 5.46 6.24 6.67 5.31 5.88 5.19 4.98 5.48
Beneish M-Score
(2.52) (1.25) (2.36) (2.53) (1.96) (1.75) (2.41) (2.42) (2.76) (2.52)
P/Operating CF
535.21 93.11 415.53 253.01 677.22 293.64 145.19 343.71 205.52 358.49
P/B ratio
6.20 2.40 3.75 4.22 6.59 8.33 4.70 5.08 4.08 4.38
Price to Tangible BV
13.17 11.86 15.05 11.80 16.15 26.37 12.94 17.50 14.81 15.22
EV/Sales
9.56 10.20 11.95 15.43 26.27 21.36 10.95 15.53 12.44 12.27
EV/EBITDA
46.90 58.77 50.38 64.68 89.22 65.94 31.63 82.71 157.32 60.17
EV/Operating CF
132.87 82.56 70.74 62.06 153.67 120.35 51.00 86.19 44.98 77.15
EV/FCF
308.33 120.09 115.98 94.66 265.25 300.03 104.81 131.03 81.98 212.32
Quick Ratio
7.49 7.99 1.77 12.03 2.47 1.92 1.83 5.31 7.03 6.82
Current Ratio
8.74 9.63 2.12 13.28 2.83 2.48 2.47 6.74 8.41 8.37
Net Debt/EBITDA
(2.18) (3.04) (1.96) (4.66) (4.15) (1.13) (0.75) (1.45) (4.62) (1.50)
Debt/Assets
32.98% 13.35% 13.36% 16.91% 14.18% 15.15% 16.42% 20.47% 18.57% 18.38%
Debt/Equity
0.56 0.17 0.17 0.22 0.18 0.20 0.22 0.30 0.27 0.26
Asset Turnover
0.48 0.27 0.26 0.25 0.22 0.31 0.33 0.24 0.22 0.26
Operating CF/Net income
0.64 0.62 1.97 3.14 1.05 0.93 0.93 3.20 (6.87) 2.40
Capex/Depreciation
(0.80) (0.52) (0.70) (0.82) (0.69) (1.43) (2.53) (0.55) (0.39) (0.27)
Interest Coverage
4.24 2.17 3.87 3.88 6.48 14.83 193.35 19.06 (1.69) 2.56
ROE
8.01% 7.46% 2.75% 2.56% 4.63% 7.82% 10.16% 1.84% (1.30%) 2.40%
ROA
5.37% 5.49% 2.19% 1.97% 3.63% 6.02% 7.61% 1.33% (0.90%) 1.69%
ROIC
8.17% 1.69% 3.09% 2.97% 4.03% 6.95% 8.25% 1.66% (1.26%) 1.83%
Return on Tangible Assets
6.56% 11.81% 9.33% 3.34% 9.22% 18.83% 23.70% 3.08% (2.24%) 4.12%
Average Days of Receivables
55.98 71.68 67.26 58.98 71.14 63.92 52.94 71.67 77.16 78.41
Research and Development Expense of Revenue
7.04% 6.14% 8.15% 7.20% 5.51% 5.11% 5.48% 6.76% 6.81% 7.34%
Selling, General and Administrative Expense of Revenue
29.51% 36.47% 33.86% 35.38% 32.66% 27.42% 26.93% 34.57% 41.51% 39.35%
Intangible Assets out of Total Assets
0.31 0.63 0.60 0.49 0.48 0.51 0.48 0.49 0.51 0.51
Share Based Compensation of Revenue
4.40% 4.78% 5.25% 4.75% 4.64% 4.10% 3.41% 4.04% 7.58% 4.42%
Graham Net Nets
0.06 0.06 0.05 0.07 0.05 0.02 0.04 0.02 0.03 0.03
Graham Number
6.29 15.94 10.97 14.90 27.32 40.92 51.03 23.06 0.00 27.08
Earnings Yield
1.12% 1.97% 0.72% 0.49% 0.59% 0.88% 2.07% 0.37% (0.31%) 0.53%
Free Cash Flow Yield
0.31% 0.85% 0.87% 0.99% 0.36% 0.33% 0.93% 0.75% 1.20% 0.46%
Revenue per Share
3.11 3.69 4.43 5.59 6.97 12.19 14.45 11.35 11.34 13.13
Operating CF per Share
0.22 0.46 0.75 1.39 1.19 2.16 3.10 2.04 3.14 2.09
Capex per Share
(0.13) (0.14) (0.32) (0.48) (0.50) (1.30) (2.40) (0.70) (0.59) (0.45)
Free Cash Flow per Share
0.10 0.31 0.43 0.91 0.69 0.87 0.70 1.34 2.55 1.63
Cash per Share
4.22 4.54 4.43 11.12 13.65 10.98 11.25 13.48 13.54 13.65
Shareholders Equity per Share
5.03 15.47 14.06 21.92 29.10 31.81 34.45 35.26 35.27 37.45
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
5.03 15.47 14.06 21.92 29.10 31.81 34.45 35.26 35.27 37.45
Free Cash Flow
3.24 12.00 18.73 44.06 36.28 47.74 38.74 74.93 142.49 91.93
Working Capital
163.08 217.57 145.90 593.52 583.43 556.42 593.92 946.40 939.25 1,001.56
Capital Expenditures
(4.28) (5.45) (14.04) (23.15) (26.34) (71.28) (133.35) (38.99) (32.90) (25.49)
Net Current Asset Value
64.00 90.81 116.69 301.48 528.65 323.39 377.22 245.01 209.09 293.82
EV/EBIT
62.56 102.87 89.20 115.60 137.83 85.64 39.06 205.82 0.00 164.20
Capex to Sales
0.04 0.04 0.07 0.09 0.07 0.11 0.17 0.06 0.05 0.03
Price to Operating Income
65.47 101.17 88.82 123.93 144.24 87.12 39.99 209.42 0.00 167.03
Other line items
Depreciation/Fixed assets
0.36 0.47 0.62 0.59 0.57 0.40 0.28 0.34 0.43 0.51
Cash ROIC
0.80% 1.39% 2.05% 2.40% 1.44% 1.76% 1.31% 2.27% 4.38% 2.69%
Accounts Receivable Turnover
7.63 6.45 6.11 6.81 6.37 7.10 6.86 5.26 4.91 5.04
Accounts Payable Turnover
8.00 10.86 9.74 10.87 11.07 10.52 10.85 15.02 13.92 11.33
Inventory Turnover
2.21 2.11 2.13 2.45 2.09 2.00 1.64 1.61 2.08 2.25
Average Days of Payables
39.21 39.64 44.24 35.01 39.34 47.31 29.08 20.18 32.60 31.12
Days of Inventory on Hand
191.31 212.33 178.27 168.04 221.43 241.12 251.49 208.65 145.03 176.75
Average Receivables
13.71 21.89 31.75 39.71 57.53 94.40 116.83 120.20 129.14 146.35
Average Payables
5.89 6.17 8.89 10.96 14.15 26.54 31.88 23.56 25.85 31.07
Average Inventory
21.35 31.85 40.63 48.55 74.93 139.76 211.39 220.30 172.64 156.71
Average Assets
217.58 516.22 759.07 1,087.37 1,651.50 2,130.62 2,444.98 2,681.39 2,830.43 2,889.68
Average Common Equity
145.76 380.16 603.56 837.67 1,294.46 1,639.61 1,830.38 1,937.77 1,968.78 2,039.42

Fold the line items

Columns are period end dates